ImmunoMet Therapeutics Issued Composition of Matter Patent by the United States Patent and Trademark Office for IM156, Mitochondrial OXPHOS Inhibitor > Investors & Media

본문 바로가기


Investors & Media

ImmunoMet Therapeutics Issued Composition of Matter Patent by the United States Patent and Trademark Office for IM156, Mitochondrial OXPHOS Inhibitor

Date :
October 25, 2016

news_logo.png


ImmunoMet Therapeutics Issued Composition of Matter

Patent by the United States Patent and Trademark Office for

IM156, Mitochondrial OXPHOS Inhibitor

 

Houston, TX, October 25, 2016 -- ImmunoMet Therapeutics, a development stage

biotechnology company focused on immuno-oncology and immune cell metabolism to

enhance anti-cancer immunity and disrupt cancer cell growth, today announced that the

United States Patent and Trademark Office has issued U.S. Patent No. 20140179660 for

IM156, a mitochondrial oxidative phosphorylation (OXPHOS) inhibitor. The patent expires in

2031 and is entitled “N1-Cyclic Amine-N5-Substituted Phenyl Biguanide Derivatives,

Methods of Preparing the Same and Pharmaceutical Composition Comprising the Same.”

IM156 is a new chemical entity that is designed to be used as a combination therapy in

difficult-to-treat, drug resistant and relapse cancers, addressing the limitations of current

cancer therapies. Patents for IM156 have been granted in China, Japan, and Korea, and

patents are pending in the EU.

 

Sung-wuk Kim, Chief Executive Officer at ImmunoMet Therapeutics, said, “We are pleased

to announce the issuance of this patent in the United States, which is important to

increasing the value of IM156. This will provide 16 years of patent coverage for the company

to pursue multiple indications, and we plan to initiate our Phase 1 study for IM156 in early

2017. 

 

About ImmunoMet Therapeutics

 

ImmunoMet Therapeutics, a development stage biotechnology company, is dedicated to

developing innovative oncology products to improve the quality of life and make a

meaningful difference in the lives of cancer patients. The Company, a spinoff of HanAll

BioPharma and headquartered in Houston, is focused on immuno-oncology targeting

immune suppressor cells (ISC) and immune cell metabolism, which are designed to enhance

anti-cancer immunity, disrupt cancer cell growth, and reverse immunosuppression in tumor

microenvironments. The Company’s novel technology addresses the high unmet medical

need to treat drug resistant, relapse cancers and improve response rates of immuno-

oncology treatments. For more information about the Company, please visit

www.immunomet.com.


Contacts

 

Joseph T. Schepers: Investor Relations and Communications, 919-616-1923,

joeschepers@immunomet.com 

Bryan Kim: Chief Technology Officer, 949-554-7429, hwkim@immunomet.com 

  

 


Copyright © ImmunoMet. All rights reserved.